Funding lifts infant HIE drug race

Fresh financing for an experimental therapy targeting brain injury in newborns has sharpened attention on one of neonatal medicine’s hardest gaps: the absence of any approved drug for hypoxic-ischaemic encephalopathy, or HIE. The trigger this month was ReAlta Life Sciences’ $40 million financing round to push pegtarazimod through its mid-stage STAR trial in babies with moderate or severe HIE, alongside the standard cooling treatment that remains the field’s only established intervention.

HIE is caused by a lack of oxygen and blood flow to a baby’s brain before, during or shortly after birth, and it can lead to death, cerebral palsy, epilepsy, cognitive impairment and lifelong developmental disability. Published reviews and company disclosures place incidence in high-income countries at roughly one to three cases per 1,000 live births, while rates in lower-income settings can be markedly higher. That burden helps explain why even an early-stage funding event is drawing wider industry and clinical interest.

For now, therapeutic hypothermia remains the backbone of treatment. Updated paediatric guidance published in January reaffirmed cooling within six hours of birth for 72 hours as the standard of care for moderate-to-severe HIE, with proven if limited benefit. Even supporters of cooling describe it as an incomplete answer, because many infants still die or go on to suffer major neurological injury despite being treated promptly. That is the opening drug developers are now trying to exploit.

ReAlta’s pitch is that pegtarazimod could become the first medicine to directly blunt the inflammatory cascade that follows the original oxygen-deprivation event. The company says the peptide is designed to inhibit complement activation at C1, myeloperoxidase activity and neutrophil extracellular trap formation, mechanisms implicated in secondary injury after HIE. Its STAR study, listed as NCT05778188, is a randomised, double-blind, placebo-controlled Phase II trial enrolling newborns at 13 neonatal intensive care sites in the United States. ReAlta has tied the new cash to completion of the trial, a top-line data readout and an end-of-Phase II meeting with the US Food and Drug Administration.

That does not mean an approved HIE drug is imminent. The financing marks progress, but pegtarazimod is still in Phase II, and the company’s own language points to upcoming regulatory discussions rather than a filed application. The more accurate reading is that the field is edging closer to a more formal regulatory path after years of stalled or inconclusive work, rather than standing on the brink of an approval. That distinction matters in an area where parents and clinicians have heard hopeful signals before.

One reason for the caution is the mixed record of earlier candidates. Erythropoietin, long viewed as a promising neuroprotective add-on to cooling, failed to improve the main outcome of death or neurodevelopmental impairment in the HEAL Phase III trial. Subsequent analyses have reinforced the conclusion that adding high-dose erythropoietin to therapeutic hypothermia did not produce the hoped-for clinical gain. Those results forced the field to confront a difficult reality: strong biological rationale does not necessarily translate into measurable benefit in newborn HIE.

Even so, the pipeline has not gone quiet. Neuren Pharmaceuticals said in February that it had received FDA feedback on NNZ-2591 for HIE, with the agency broadly accepting the design of an initial study to open an investigational new drug application, while asking for additional juvenile animal data before dosing neonates. Neuren said it still planned to begin that clinical study later in 2026. Separately, FDA records show Chiesi Farmaceutici received orphan-drug designation on 1 April for a recombinant human mutant nerve growth factor for neonatal HIE, signalling another entrant moving through the formal regulatory system.

Scientific literature suggests why companies continue to press ahead despite repeated setbacks. Reviews of HIE research describe the disorder not as a single short-lived insult, but as a multi-phase process in which energy failure is followed by inflammation, excitotoxicity, oxidative stress and cell death. That understanding has widened interest in combination approaches, where a drug is paired with cooling rather than trying to replace it. Preclinical work on agents including modified nerve growth factor, melatonin and other neuroprotective candidates has kept alive the argument that timing, target selection and patient stratification may decide whether the first successful therapy emerges.